Feniton

Quick links to important sections

Feniton

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Feniton

Property Description
Active ingredient Phenytoin (Diphenylhydantoin)
Form Oral Capsule, Tablet, Suspension, Injection
Pharmacological class Anticonvulsant (Antiepileptic Drug)
Origin Synthetic
General Purpose Stabilizing nerve cell electrical activity

Defining Feniton: Phenytoin, the Core Active Ingredient

Feniton is the trade designation for the synthetic, prescription-only medication containing the active ingredient Phenytoin (INN), also chemically identified as Diphenylhydantoin. The drug is classified as an Anticonvulsant or Antiepileptic Drug (AED), belonging specifically to the Hydantoin derivative class. This structural classification distinguishes it from newer generations of AEDs, yet its efficacy remains clinically recognized for controlling excessive electrical impulses in the brain. The medication functions as a stabilizing agent within the central nervous system.


Composition and Available Forms

The medication is a single-ingredient product, containing only Phenytoin (often compounded as Phenytoin Sodium for enhanced stability) alongside necessary excipients. The active substance is provided in several pharmaceutical preparations to meet various patient needs, including both oral and parenteral forms. For long-term patient use, Phenytoin is supplied in solid oral forms such as immediate-release and extended-release capsules and chewable tablets, or as a liquid oral suspension often used in pediatric patients. For critical interventions, a sterile solution for Injection is prepared for rapid administration via the Intravenous route.


How Phenytoin Stabilizes Electrical Signals

Phenytoin functions primarily as a voltage-gated sodium channel blocker, a key physiological action that prevents the brain's nerve cells from becoming hyper-excitable. This mechanism limits the influx of sodium ions into the neurons, which are essential for generating and propagating electrical signals. The result of this action is the reliable stabilization of the neuronal membrane, which limits the cell’s capacity for rapid, repetitive firing. This overall effect supports the general purpose of maintaining stable electrical function and mitigating uncontrolled electrical spread in the brain.

Regulatory References

  1. Phenytoin - StatPearls - NCBI Bookshelf - NIH

What side effects are possible with Feniton?

Possible side effects and safety information

Feniton (Phenytoin) is associated with an official safety profile that documents adverse reactions across several physiological systems, ranging from frequently observed effects to rare, serious systemic events. Regulatory classification designates certain central nervous system effects as Most Common (incidence 10% in clinical data), including nystagmus (involuntary eye movement), ataxia (lack of coordination), and somnolence (drowsiness).

Serious adverse reactions, though infrequent, are explicitly documented in regulatory labels. These include potentially fatal events such as Severe Cutaneous Adverse Reactions (SCARs), specifically Stevens-Johnson Syndrome (SJS) and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). Other serious events involve the Cardiovascular System (e.g., asystole and severe hypotension) and the Hepatic System (acute hepatic failure).

The official profile specifies population-specific safety considerations. For instance, an association is noted between the risk of SJS/TEN and the *HLA-B15:02 allele in certain populations. Furthermore, exposure during pregnancy carries a documented risk for congenital malformations**.

Safety constraints require that Feniton is contraindicated in patients with specific pre-existing cardiac conduction abnormalities. Regulatory documents also mandate that abrupt discontinuation of the medicine should be avoided due to the potential for precipitating increased seizure frequency, including Status Epilepticus. The risk of Suicidal Thoughts or Behavior is noted as a possibility, observed as early as the first week of treatment.

Overdose and Emergency Response

Feniton overdose is defined in official regulatory labeling as a progression of central nervous system (CNS) toxicity. Documented clinical manifestations include early signs such as nystagmus (involuntary eye movement), ataxia (unsteadiness), and slurred speech. As toxicity increases, these symptoms may advance to confusion, lethargy, and ultimately coma and respiratory depression.

Severe outcomes involve the cardiovascular system, which may include severe hypotension and cardiac arrhythmias (such as asystole and ventricular fibrillation). These life-threatening events are particularly associated with the intravenous administration of the drug. Critically ill and elderly patients, as well as those with hepatic or renal impairment, are noted in official labels to be at heightened risk for severe complications in an overdose setting.

Regulatory guidance states that anyone suspecting an overdose must seek immediate medical attention or call the local emergency number and contact the Poison Control Center. The medication must be immediately discontinued. Management is symptomatic and supportive, as no specific antidote is known. Officially described emergency procedures include ensuring airway support, continuous monitoring of vital signs, and conducting an electrocardiogram (ECG) and phenytoin serum level blood tests.

Therapeutic Uses of Feniton

What Feniton Treats: Main Uses and Benefits

Feniton is used in situations involving certain distressing symptoms. It is commonly used to help with symptoms linked to organ-specific functional stress. The medication is commonly used across conditions presenting with acute or episodic manifestations.

Feniton is applied in addressing several conditions, including conditions characterized by periods of heightened symptoms, such as epilepsy (managing symptoms related to generalized tonic-clonic and complex partial seizures), trigeminal neuralgia (severe nerve pain), and specific ventricular arrhythmias. It is also relevant in contexts involving heightened systemic burden due to neurological recovery. The medication provides support that helps ease the overall symptom burden by addressing symptoms that become more disruptive during flare-ups.

“This medication assists with maintaining functional stability during episodes of heightened discomfort.”

Quick Fact: Relief of Symptomatic Discomfort

Feniton may assist with maintaining functional stability during episodes, and is applied in clinical settings that involve acute or unstable symptom patterns.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who can and cannot use Feniton?

The eligibility for Feniton (Phenytoin) is officially defined by regulatory bodies, establishing strict rules for use based on patient history, age, and physiological status.

Contraindications: Must Not Be Used

Feniton is contraindicated in patients with a known hypersensitivity to phenytoin or other hydantoins, or those with a history of prior acute hepatotoxicity (liver damage) attributed to the drug. It is also prohibited if a skin rash recurs after attempting to resume therapy. For intravenous use, it is contraindicated in patients with specific cardiac conduction issues like sinus bradycardia or certain types of atrioventricular block.

Restricted and Conditional Use

Population Group Regulatory Status Constraint Context
Women of Childbearing Potential Restricted Use Should not be used unless benefits outweigh risks; effective non-hormonal contraception is required due to risk of foetal harm.
Hepatic or Renal Impairment Conditional Use Patients with impaired liver or kidney function may show early signs of toxicity and require careful monitoring of drug levels.
Older Adults (Geriatric) Conditional Use May require lower, less frequent dosing due to potentially decreased clearance and increased risk of toxicity.
Absence (Petit Mal) Seizures Not Effective Phenytoin is not effective for this specific type of seizure; combined therapy may be necessary.

What should I know about interactions with other medicines?

Phenytoin’s interaction profile is defined primarily by its role as a potent inducer of hepatic enzymes, notably the CYP2C and CYP3A systems. This enzyme induction may lead to a decreased plasma exposure of many co-administered medicinal products, which includes drugs such as Oral Contraceptives and the anticoagulant Warfarin. Conversely, Phenytoin is metabolized by the CYP2C9 and CYP2C19 pathways, and co-administration with inhibitors (e.g., Cimetidine, Fluconazole) is documented to increase Phenytoin serum concentrations.

A formal interaction restriction dictates that co-administration with the antiviral Delavirdine is contraindicated. Other high-level interaction classifications include the documented additive risk of Hyperammonemia when co-administered with Valproate.

Regarding timing constraints, administration of Phenytoin must be separated by at least three hours from enteral feeding preparations and substances like Antacids to mitigate a regulatory-documented reduction in absorption. Chronic and acute alcohol use also carry opposing, but specific, risks to Phenytoin serum levels. Furthermore, specific populations, particularly those with hepatic impairment or hypoalbuminemia, exhibit an increased unbound fraction of the drug, which requires careful assessment of total serum concentration results.

Mechanism of Action

Feniton (Phenytoin) modulates neuronal activity primarily through its interaction with voltage-gated sodium channels (NaV). The compound functions as a non-specific sodium channel inhibitor, targeting channels predominantly within the central nervous system (CNS). It displays a preference for channels in their inactive state, binding to a site distinct from the alpha-subunit's pore. This binding stabilizes the inactive conformation of the channel, resulting in a prolonged refractory period and a slower rate of recovery to the excitable state. Intracellularly, this molecular mechanism reduces the flux of Na^+ ions across the neuronal membrane. The key consequence of this interaction is the attenuation of high-frequency repetitive firing of action potentials in neurons. By limiting the neuron's capacity for sustained, rapid depolarization, Feniton effectively modulates the system-level physiological consequence of uncontrolled, synchronous electrical activity across neuronal networks. Secondary interactions include minor inhibition of voltage-dependent L-type calcium channels and potential modulation of potassium channel conductance, contributing to overall membrane stabilization and reduced excitability.

Dosage and Administration Information

How to use Feniton — Administration Guidelines

Feniton (Phenytoin) is officially administered via two principal routes: Oral for long-term maintenance and Intravenous (IV) for acute, supervised use. The Intramuscular (IM) route is generally cited as requiring a dose increase due to erratic absorption and is not recommended for urgent needs.

Administration Scope Administration Instruction
Oral Adult Maintenance The standard daily amount is typically 300 mg, administered as a single dose or divided into two to three doses. Initial loading doses for non-emergency situations may total 1,000 mg.
IV Administration Rate Infusion must not exceed 50 mg per minute in adults. Pediatric IV loading doses should not exceed 1 to 3 mg/kg/minute or 50 mg/minute, whichever is slower.
Frequency and Adjustment A minimum period of seven to ten days is required between any change in dosage to allow the medicine to reach stable concentrations in the body.
Special Handling The IV solution must be diluted only in normal saline (0.9% NaCl) and must be administered immediately after preparation using an in-line filter. Oral administration should be separated from continuous enteral tube feedings to optimize absorption.
Transitioning Forms Switching between different oral formulations (e.g., immediate-release, extended-release, or suspension) is officially cited as needing close oversight due to variable bioavailability.

The instructions establish a highly structured procedural framework for Phenytoin use, specifying exact dose ranges, mandatory infusion conditions, and minimum time constraints between dose modifications. These rules define the standardized approach to initiating, maintaining, and gradually discontinuing therapy.

Recent Clinical Evidence

Research evidence / Overview of Studies for Feniton

Evidence for Use in Epilepsy (Seizure Management)

Feniton has been extensively studied for managing the symptoms associated with certain types of epilepsy, including generalized tonic-clonic and complex partial seizures. The evidence base for this area of study includes many formal Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews conducted over several decades. These studies typically examined outcomes related to the duration of seizure-free periods and the time until symptoms recurred. Research also explored the reasons why patients might stop treatment, which provides context on both seizure control and tolerability in the observed populations.

However, a key limitation is that many of the core trials are considered historical in the research landscape. While the research provided context about the medication when compared to other early anti-seizure medications, there is limited information from recent, large-scale RCTs directly comparing Feniton to the newest generation of anti-seizure medications. This means the evidence base for comparison to very modern therapies is not fully established by current comparative data.

Evidence for Other Studied Conditions

Feniton was also studied for conditions such as the severe nerve pain of trigeminal neuralgia. The research for this use largely consists of small, older comparative studies, case series, and observational reports, which describe patterns observed in outcomes related to physical discomfort. However, the certainty remains low for this indication because there is a lack of modern, high-quality, placebo-controlled RCTs to provide high certainty regarding the findings reported in older data.

Furthermore, Feniton was observed in a research context involving certain ventricular arrhythmias (irregular heart rhythms). Evidence related to this use is limited and mainly describes acute, short-term responses in highly specific populations. Current scientific guidelines indicate that this specific application is not favored when compared to newer, more rigorously studied treatments for these conditions.

What is Still Uncertain About Feniton’s Research

The research on Feniton highlights several areas where certainty remains low or where data needs updating. Primarily, the evidence quality varies across studies, with the strongest research focusing on epilepsy. Comparative evidence is lacking against most modern, widely used anti-seizure medications. The evidence for non-epilepsy uses, such as trigeminal neuralgia, is limited and primarily observational, meaning the research examined showed variable findings across different reports. This research provides context but not individual predictions, and the findings describe group patterns, not personal outcomes.

Key Studies & References

  1. Trigeminal Neuralgia Crisis – Intravenous Phenytoin as Acute Rescue Treatment (Retrospective Cohort Study)
  2. Epilepsies: diagnosis and management (NICE Clinical Guideline CG137)
  3. Phenytoin Toxicity (Reference for the context of its older use as an antiarrhythmic and toxicity data)

Frequently Asked Questions (FAQ)

Common questions about Feniton (FAQ)

Q: Are there any common interactions between Feniton and over-the-counter pain relievers?

Official documentation describes Feniton as an inducer of the CYP450 enzyme system, which may increase the rate at which certain co-administered medications are broken down. This general mechanism suggests potential interactions that could reduce the concentration of some drugs, which may include specific over-the-counter pain relievers.

Q: Is it true that Feniton can interact with certain antidepressants?

Feniton is broken down (metabolized) by the CYP2C9 and CYP2C19 enzyme pathways in the body. Official documents state that other medications, including certain classes of antidepressants, can inhibit these pathways, potentially leading to higher concentrations of Feniton in the blood.

Q: How long does Feniton stay in the body?

The amount of time Feniton stays in the body is often measured by its elimination half-life. According to official product information, this duration can vary significantly between individuals but is generally described as being between 7 and 42 hours.

Q: What does research say about the long-term use of Feniton?

Feniton has been widely studied as a chronic maintenance therapy over several decades. Research has focused on its seizure control and tolerability over the long term. However, the regulatory evidence base for comparison to the newest generation of similar medicines is noted as limited.

Q: What if I experience mild dizziness after taking Feniton?

Official regulatory documents list several Central Nervous System (CNS) effects that can be related to unsteadiness. These reported adverse reactions include dizziness, ataxia (a lack of muscle coordination), and nystagmus (involuntary eye movement).

Q: Is the feeling of 'brain fog' a known side effect of Feniton?

The official safety profile lists CNS effects such as somnolence (drowsiness) and ataxia as common reactions. These symptoms are recognized as potentially affecting a person's mental clarity and concentration.

Q: Is there published evidence regarding Feniton's use in children or teenagers?

Yes, the medicine is officially approved for use in pediatric populations. Its use is supported by prescribing information which addresses its use and dosage needs.

Q: What does 'contraindicated' mean in relation to Feniton use?

'Contraindicated' is a formal medical term used in regulatory documents. It describes a specific medical condition or circumstance where official regulatory guidance advises against the use of the drug. This is because the risks of harm are considered to significantly outweigh any possible benefit.

Q: What kind of monitoring is typically required while taking Feniton?

Official regulatory guidance describes that routine monitoring is typically recommended for patients using Feniton. This often includes periodic checks of serum drug concentrations (blood levels) to guide therapy, as well as monitoring of blood cell counts and liver function.

Q: Why do some people report feeling restless after taking Feniton?

Official documentation reports various psychiatric and nervous system effects. These can include insomnia and transient nervousness during treatment. The potential for agitation or mood changes is also captured in the reporting on adverse events.

Q: Are there any research themes focusing on optimizing Feniton's use?

Research cited in official documents focuses on understanding the drug's variable effect across different patients. This includes studying the association between Feniton use and certain genetic factors, such as the *HLA-B15:02** allele, which can help guide risk assessment in certain populations.

Q: Is there a specific maximum dose mentioned in the prescribing information for Feniton?

Official prescribing information states the typical daily maintenance dose for adults. However, the label does not specify a single, absolute maximum daily dose, as required dosages are highly individualized based on the patient's condition and measured drug levels in the blood.

Q: How quickly does Feniton usually start working?

The time it takes for the drug to start working can vary by the form used. For the oral formulation, official literature indicates that it may take 7 to 10 days of consistent administration to achieve stable therapeutic concentrations in the body.

Q: What is the typical time frame for noticing the effects of Feniton?

Because it takes time for the body to build up to a stable level of Feniton, the maximum observable therapeutic effect may not be fully apparent right away. Official information indicates this process can take up to one to two weeks following the start of therapy or a dose change.

Q: Is Feniton a type of drug that needs to be taken long-term?

Feniton is formally described in official medical summaries as a maintenance therapy. This means its intended use is often for the chronic, long-term management of certain conditions.

Q: Can Feniton cause weight gain, according to official information?

Official safety documents and adverse event reporting for Feniton include reports of weight gain. This is generally cited in the official literature as a non-common side effect.

Q: Is Feniton the same kind of drug as [Similar Drug Name]?

Feniton contains the active ingredient Phenytoin, which is officially classified as an Anticonvulsant and a Hydantoin derivative. This classification defines its specific pharmacological type and distinguishes it from other classes of medications.

Q: Can I take Feniton with food, or does it matter?

Official labeling indicates that taking the oral formulation with food may help to reduce gastrointestinal irritation. However, official labeling requires the separation of oral administration from certain substances, such as antacids and enteral tube feeds, to optimize absorption.

Q: Is there a generic version of Feniton available?

Yes, the active ingredient in Feniton, Phenytoin, is widely registered and available in generic form. Phenytoin is marketed by multiple manufacturers in various approved oral and injectable dosage forms.

Q: Does Feniton have any known effects on appetite?

Official safety data includes reports of changes to appetite. Specifically, official documents list anorexia (loss of appetite) as a reported adverse event.

Q: Can Feniton cause dry mouth?

Official safety documentation lists dry mouth as a reported adverse reaction associated with Feniton.

Q: How does the official literature describe the potential for Feniton to cause dependence?

The regulatory label addresses the potential for abuse and dependence in a dedicated section. Feniton is generally not classified as a substance with high addictive potential.

Q: What is the recommended approach if a user misses a dose of Feniton?

Official patient information describes the recommended approach for a missed dose. This guidance typically advises that if the user misses a dose and remembers soon after, the dose should be taken, but if it is very close to the next scheduled dose, the missed dose should generally be skipped.

Q: Can Feniton be taken with supplements or herbal products?

Official documents caution that Feniton interacts with the CYP450 enzyme system, which can be affected by various herbal and supplemental products. Official regulatory documents caution that potential interactions with supplements or herbal products should be considered.

Q: Is it true that official sources advise against driving when first starting Feniton?

Regulatory documents contain clear warnings that Feniton may cause side effects like drowsiness, dizziness, and visual changes. These effects can impair a person's ability to safely drive or operate machinery.

Q: Can Feniton affect blood sugar levels?

Official regulatory documentation notes that Feniton may be associated with hyperglycemia, which is the medical term for high blood sugar levels.

Q: Are there any reports of hair loss associated with Feniton?

Hair loss, medically known as alopecia, is listed in the official adverse event reporting. It is reported in post-marketing or non-common clinical data.

Q: Does taking Feniton interfere with common lab tests?

Yes, official documents state that Feniton may interfere with the results of certain common laboratory tests. This includes tests used to measure blood sugar, thyroid function, and certain steroid levels.

Q: What is the difference between an adverse event and a side effect, regarding Feniton?

Official sources use both terms to describe undesirable drug-related experiences. An adverse event is generally defined as any undesirable experience, while a side effect is typically a known or expected undesirable reaction mentioned in the official labeling.

Q: What are the official guidelines about Feniton and breastfeeding?

Official regulatory text confirms that Feniton is excreted into human milk. Official regulatory text notes that this guidance includes consideration of the potential risk of exposure to the nursing infant versus the benefits of breastfeeding for the mother.

Q: Is it normal to have vivid dreams while taking Feniton?

Official adverse event reporting includes sleep disturbances and reports of vivid dreams as reported psychiatric or Central Nervous System side effects.

How should Feniton be stored and disposed of?

Storage and Disposal Conditions for Fenitoin (Phenytoin)

Fenitoin must be stored at Controlled Room Temperature (20 C to 25 C), with permitted excursions up to 30 C. The medication requires strict protection from light and moisture. Oral formulations must be kept in a tight, light-resistant container and remain tightly closed. The liquid suspension formulation must not be frozen.

Handling and Disposal

For public safety, Fenitoin must always be stored out of the reach of children. Unused portions of the single-dose injectable product should be immediately discarded, and outdated medicine must not be kept. For correct discarding procedures, the official labeling directs users to ask a healthcare professional or pharmacist how to dispose of any unused product.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Feniton found in:

A-Z Index: